Definium Therapeutics reports positive Phase 3 results for oral LSD anxiety drug DT120

Definium Therapeutics announced Monday that its experimental oral LSD formulation, DT120, achieved positive outcomes in a Phase 3 trial targeting an anxiety disorder.

The trial, the company's third Phase 3 study this year, demonstrated statistically significant improvement in primary efficacy endpoints compared with placebo, according to the company's release.

Following the favorable data, Definium said it will prepare a submission to the U.S. Food and Drug Administration, aiming to seek approval for the indication.

The results add to growing interest in psychedelic‑based therapies for mental health, though the drug remains under investigation and not yet available to patients.